about
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.KRAS mutation in lung metastases from colorectal cancer: prognostic implications.Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.Regorafenib for the treatment of unresectable hepatocellular carcinoma.Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.PD-019ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA).Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipies.Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyEffect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational StudyShaping the landscape of immune oncology in hepatocellular carcinomaEmergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment StrategiesBiomarkers in Hepatocellular Carcinoma--LetterFatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient SelectionLenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to dateEpidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
P50
Q34196471-40CD73BE-A142-4F65-90DF-69466F085AB2Q34253748-957B483F-0517-4649-AD1B-CDF99F01F60EQ36528345-593F66EC-10CF-4D2A-A206-F119DAE409FEQ36779175-58EA8265-A638-47E5-9597-D206DF1B77F2Q37687269-DD568CB6-E0E3-4EAB-92F3-3991BDE20B1EQ38062681-C4F51DEA-8E69-419A-BB95-1241122B2295Q38674803-27DD008F-B6DD-4B85-A3FB-0503FD09B5ADQ39466467-1A840355-3C60-44BF-A884-BC60FB6E9890Q40215577-B2DC1C71-0D05-4318-BD2E-8863279C9352Q40224897-4663AA99-13A6-45FF-A6F8-F6D7AA560E22Q40619773-893E0E61-48D4-4F62-8952-E8F81C99E587Q41652822-B45B678F-C6D5-4592-89CF-B4DE2077C9CEQ41942214-EB3C5C8E-F186-4199-801B-D5BA0950AB8AQ42364897-412BE595-8642-4327-98C9-F7DE74D1FE10Q43010373-0B9B4B6B-EAEC-4B54-8B02-AE26BE66E3F9Q43211029-E689A39B-9058-422E-926D-8DA741AFA036Q43508188-9C6E92FA-8499-4405-8F22-37E020C2C7E9Q43760313-1E5BF0AD-B89F-46E1-B145-246155E60035Q46381917-DA3004F7-F347-4D89-B45D-7BF57B931877Q46884385-89B8B4D4-2AAD-4743-8841-7626DC519D37Q46893706-2E92E83F-AC68-400E-A2C4-55BD6244CE23Q46903224-FA86A172-814A-42AF-8D6A-D3C4EE27BCFCQ47597081-4802FB6C-4AB9-475C-8393-D0B2851EA5AEQ50103787-1549B574-7481-40D6-9FE0-054CB7E0EEDEQ50978599-F197C1C2-3EB9-491F-BBC7-A55B749FCCCAQ52682078-0D91C5C1-FE9B-481C-9E4A-EBC14DBCD719Q52953584-96FB35C0-9B65-4A48-BE71-A3E47E98C395Q53097045-080233EE-907D-41DE-8596-37BC5B877035Q53550371-849FBA9C-7D21-4698-812F-C29DF591AF5AQ55600804-A5E98B3F-829D-4014-B341-140991C40237Q56384328-B003B028-202D-4EA8-8042-91EA34A18AEBQ61054481-907B47E0-06DD-4CA7-AA8F-16805BC70C69Q61054485-EE95CAE1-1ADD-47FA-9B25-43A102C38552Q61054490-D7CE75FD-9FE2-4DEA-85E6-15B6D6DC23D2Q61054495-BA592463-C5EA-43DD-A9AC-0B3E34294B39Q61054507-82AF070C-F75C-4DE5-A5BF-6C44B58973F4Q61054511-BDBFC1CE-B071-460A-829D-5A3180783735Q61805290-B2FBB70C-0531-4FCE-B624-92514773D1FBQ79394028-0940380A-2A8C-4AD3-B073-28EEDD5924F0Q79843530-C38D74FA-3AFC-4567-8096-AEC67F4CF861
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Personeni
@ast
Nicola Personeni
@en
Nicola Personeni
@es
Nicola Personeni
@nl
Nicola Personeni
@sl
type
label
Nicola Personeni
@ast
Nicola Personeni
@en
Nicola Personeni
@es
Nicola Personeni
@nl
Nicola Personeni
@sl
prefLabel
Nicola Personeni
@ast
Nicola Personeni
@en
Nicola Personeni
@es
Nicola Personeni
@nl
Nicola Personeni
@sl
P106
P1153
11241441400
P21
P31
P496
0000-0002-7995-272X